FDA Officials Say Potency Problems Main Reason for NTI Drug Recalls
This article was originally published in The Gold Sheet
Executive Summary
FDA officials said that use of quality by design as well as “equivalence by design” will help drug manufacturers develop better generic substitutions of narrow therapeutic index (NTI) drugs to address the high rate of recalls associated with these products due to potency problems.
You may also be interested in...
ANDAs For Narrow Therapeutic Index Drugs May Need Crossover Studies
FDA’s challenges in creating a more specific definition of narrow therapeutic index drugs were on clear display at the most recent advisory committee meeting on the topic: There’s wide support for the project, but equally broad concern that it needs to be more carefully tailored.
Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company
The privately-owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.
Synthekine Joins Quest To Tame IL-2 In Cancer Therapies
First clinical data from Synthekine’s IL-2 candidate and that ofrivalsMedicennawere presented at the AACR, suggesting there’s life in the modality yet.